Potential role of targeted therapies in the treatment of triple-negative breast cancer

Anti-Cancer Drugs

Volumn 27, Issue 3, 2016, Pages 147-155

  Jia, Lee Yueh ^a   Shanmugam, Muthu K ^a   Sethi, Gautam ^a,b   Bishayee, Anupam ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CURTIN UNIVERSITY   (Australia)

^c Larkin Health Science Institute   (United States)

Author keywords

Angiogenesis; Chemotherapy; Targeted therapies; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AZACITIDINE; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; INIPARIB; IRINOTECAN; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLATINUM DERIVATIVE; RUCAPARIB; SOMATOMEDIN C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN A; VORINOSTAT;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; TRIPLE NEGATIVE BREAST CANCER; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84957943321     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000328     Document Type: Review

References (93)

1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132:1133-1145.
2. I.A.F.C.R. IARC, Latest world cancer statistics Global cancer burden rises to 141 million new cases in 2012: marked increase in breast cancers must be addressed. Lyon/Geneva: WHO; 2013.
3. Papa A, Caruso D, Tomao S., Rossi L, Zaccarelli E, Tomao F. Triple-negative breast cancer: investigating potential molecular therapeutic target. Expert Opin Ther Targets 2015; 19:55-75.
4. Wang X, Song H, Yu Q., Liu Q, Wang L, Liu Z., et al. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. Oncol Rep 2015; 33:526-532.
5. Mancini P, Angeloni A, Risi E., Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014; 6:2187-2223.
6. Dent R, Trudeau M, Pritchard K.I., Hanna WM, Kahn HK, Sawka CA, et al Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-4434.
7. Chokunonga E, Borok MZ, Chirenje Z.M., Nyakabau AM, Parkin DM. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1 991-2010. Int J Cancer 2013; 133:721-729.
8. Wabinga H, Parkin DM, Nambooze S, Amero J. Cancer survival in Kampala, Uganda, 1993-1997. IARC Sci Publ 2011. 243-247.
9. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70.
10. Carey LA, Perou CM, Livasy C.A., Dressler LG, Cowan D, Conway K, et al Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492-2502.
11. Bauer KR, Brown M, Cress R.D., Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109:1721-1728.
12. Sorlie T, Tibshirani R, Parker J., Hastie T, Marron JS, Nobel A, et al Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-8423.
13. Oakman C, Moretti E, Pacini G., Santarpia L, Di Leo A. Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. Eur J Cancer 2011; 47 (suppl 3):S370-S372.
14. Viale G, Rotmensz N, Maisonneuve P., Bottiglieri L, Montagna E, Luini A., et al. Invasive ductal carcinoma of the breast with the 'triple-negative' phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116:317-328.
15. Bostrom P, Soderstrom M, Palokangas T., Vahlberg T, Collan Y, Carpen O., et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes 2009; 2:140.
16. Geyer FC, Lacroix-Triki M, Savage K., Arnedos M, Lambros MB, MacKay A, et al Beta-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011; 24:209-231.
17. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109:25-32.
18. Lehmann BD, Pietenpol JA Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014; 232:142-150.
19. Lehmann BD, Bauer JA, Chen X, Sanders M.E., Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
20. Masuda H, Baggerly KA, Wang Y, Zhang Y., Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19:5533-5540.
21. Feng M, Bao Y, Li Z., Li J, Gong M, Lam S., et al. RASAL2 activates RAC1 to promote triple-negative breast cancer progression. J Clin Invest 2014; 124:5291-5304.
22. Smart E, Hughes T, Smith L., Speirs V. Estrogen receptor beta: putting a positive into triple negative breast cancer? Horm Mol Biol Clin Investig 2013; 16:117-123.
23. Yan Y, Li X, Blanchard A., Bramwell VH, Pritchard KI, Tu D, et al Expression of both estrogen receptor-beta 1 (ER-beta1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-alpha)-negative early breast cancer (EBC). Ann Oncol 2013; 24:1986-1993.
24. Shanle EK, Zhao Z, Hawse J., Wisinski K, Keles S, Yuan M., et al. Research resource: global identification of estrogen receptor beta target genes in triple negative breast cancer cells. Mol Endocrinol 2013; 27:1762-1775.
25. Datta A, Loo SY, Huang B, Wong L., Tan SS, Tan TZ, et al. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget 2014; 5:5920-5933.
26. Blanchard Z, Mullins N, Ellipeddi P., Lage JM, McKinney S, El-Etriby R, et al. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One 2014; 9:e95663.
27. Bahhnassy A, Mohanad M, Shaarawy S., Ismail MF, El-Bastawisy A, Ashmawy AM, et al Transforming growth factor beta, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor A: prognostic and predictive markers in triplenegative and nontriplenegative breast cancer. Mol Med Rep 2015; 12:851-864.
28. von Minckwitz G., Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol 2012; 23 (suppl 6):vi35-vi39.
29. von Minckwitz G., Untch M, Blohmer J.U., Costa SD, Eidtmann H, Fasching PA, et al Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-1804.
30. Byrski T, Gronwald J, Huzarski T., Grzybowska E, Budryk M, Stawicka M., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28:375-379.
31. Silver DP, Richardson AL, Eklund A.C., Wang ZC, Szallasi Z, Li Q, et al Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28:1145-1153.
32. Petrelli F, Coinu A, Borgonovo K., Cabiddu M, Ghilardi M, Lonati V., et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2014; 144:223-232.
33. Agrawal LS, Mayer IA Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice? Clin Adv Hematol Oncol 2014; 12:654-658.
34. Petrelli F, Borgonovo K, Cabiddu M., Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78:8-15.
35. Saal LH, Gruvberger-Saal SK, Persson C., Lovgren K, Jumppanen M, Staaf J., et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40:102-107.
36. Liang H, Tan AR Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs 2010; 13:646-656.
37. O'Shaughnessy J., Schwartzberg L, Danso M.A., Miller KD, Rugo HS, Neubauer M, et al Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32:3840-3847.
38. Anders C, Deal AM, Abramson V, Liu M.C., Storniolo AM, Carpenter JT, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat 2014; 146:557-566.
39. Antonio Llombart C.V., Delaloge S, Morales S., Balmaña J, Amillano K., Bonnefoi HR, et al. SOLTI Group, SOLTI NeoPARP. A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). 2012 ASCO Annual Meeting, 1-5 June 2012, Chicago, Illinois, USA.
40. Min A, Im SA, Kim D.K., Song SH, Kim HJ, Lee KH, et al Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res 2015; 17:33.
41. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19-25.
42. de Ruijter A.J., van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-749.
43. Thummuri D, Kumar S, Surapaneni S.K., Tikoo K. Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer. Life Sci 2015; 130:73-80.
44. Wu MQ, Hu P, Gao J., Wei WD, Xiao XS, Tang HL, et al Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer. Asian Pac J Cancer Prev 2013; 14:287-292.
45. Sun T, Aceto N, Meerbrey K.L., Kessler JD, Zhou C, Migliaccio I, et al Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011; 144:703-718.
46. Chuang HC, Kapuriya N, Kulp S.K., Chen CS, Shapiro CL. Differential antiproliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012; 134:649-659.
47. Carey LA, Rugo HS, Marcom P.K., Mayer EL, Esteva FJ, Ma CX, et al TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615-2623.
48. Baselga J, Gomez P, Greil R., Braga S, Climent MA, Wardley A.M., et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586-2592.
49. Dickler MN, Cobleigh MA, Miller K.D., Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009; 115:115-121.
50. Gutteridge E, Agrawal A, Nicholson R., Leung Cheung K, Robertson J, Gee J. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. Int J Cancer 2010; 126:1806-1816.
51. Ueno NT, Zhang D. Targeting EGFR in triple negative breast cancer. J Cancer 2011; 2:324-328.
52. Yi YW, Hong W, Kang H.J., Kim HJ, Zhao W, Wang A, et al Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triplenegative breast cancer cells. J Cell Mol Med 2013; 17:648-656.
53. Derynck R, Muthusamy BP, Saeteurn KY Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition. Curr Opin Cell Biol 2014; 31:56-66.
54. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014; 34:280-300.
55. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10:116-129.
56. Brooks AN, Kilgour E, Smith PD Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18:1855-1862.
57. Acevedo VD, Gangula RD, Freeman K.W., Li R., Zhang Y, Wang F, et al Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007; 12:559-571.
58. Feng S, Zhou L, Nice E.C., Huang C. Fibroblast growth factor receptors: multifactorial-contributors to tumor initiation and progression. Histol Histopathol 2015; 30:13-31.
59. Haugsten EM, Wiedlocha A, Olsnes S., Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010; 8:1439-1452.
60. Jung SY, Yi JY, Kim M.H., Song KH, Kang SM, Ahn J, et al IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling. Oncol Rep 2015; 34:2731-2737.
61. Turner N, Lambros MB, Horlings H.M., Pearson A., Sharpe R, Natrajan R, et al Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29:2013-2023.
62. Andre F, Bachelot T, Campone M., Dalenc F, Perez-Garcia JM, Hurvitz SA, et al Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013; 19:3693-3702.
63. Barton VN, D'Amato NC, Gordon MA, Lind H.T., Spoelstra NS, Babbs BL, et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther 2015; 14:769-778.
64. McGhan LJ, McCullough AE, Protheroe C.A., Dueck AC, Lee JJ, Nunez-Nateras R, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 2014; 21:361-367.
65. Gucalp A, Isakoff SJ, Ingle J.N., Liu MC, Carey LA, Blackwell KL, et al Targeting the androgen receptor (AR) in women with AR + ER-/PR-metastatic breast cancer (MBC). American Society of Clinical Oncology Annual Meeting; Translational Breast Cancer Research Consortium (TBCRC); 1-5 June 2012, Chicago, Illinois, USA.
66. Collins LC, Cole KS, Marotti J.D., Hu R., Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011; 24:924-931.
67. Mrklic I, Pogorelic Z, Capkun V., Tomic S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem 2013; 115:344-348.
68. Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, et al. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 2014; 27:352-360.
69. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005; 7:513-520.
70. Gholami S, Marano A, Chen N.G., Aguilar RJ, Frentzen A, Chen CH, et al A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res Treat 2014; 148:489-499.
71. Mehta R, Katta H, Alimirah F., Patel R, Murillo G, Peng X., et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One 2013; 8:e65113.
72. Foekens JA, Peters HA, Grebenchtchikov N, Look M.P., Meijer-van Gelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61:5407-5414.
73. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-153.
74. Tomao F, Papa A, Zaccarelli E., Rossi L, Caruso D, Minozzi M., et al. Triplenegative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 2015; 8:177-193.
75. Cetin I, Topcul M. Triple negative breast cancer. Asian Pac J Cancer Prev 2014; 15:2427-2431.
76. Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol 2014; 141:462-477.
77. Robert NJ, Dieras V, Glaspy J., Brufsky AM, Bondarenko I, Lipatov ON, et al RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252-1260.
78. Brufsky A, Valero V, Tiangco B., Dakhil S, Brize A, Rugo H.S., et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012; 133:1067-1075.
79. Gerber B, Loibl S, Eidtmann H., Rezai M, Fasching PA, Tesch H, et al Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-2984.
80. Cameron D, Brown J, Dent R., Jackisch C, Mackey J, Pivot X., et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14:933-942.
81. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X., et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013; 108:1052-1060.
82. Geng SQ, Alexandrou AT, Li JJ Breast cancer stem cells: multiple capacities in tumor metastasis. Cancer Lett 2014; 349:1-7.
83. Kagara N, Huynh KT, Kuo C, Okano H., Sim MS, Elashoff D, et al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am J Pathol 2012; 181:257-267.
84. Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M., et al. Prognostic value of cancer stem cells markers in triplenegative breast cancer. Biomed Res Int 2015; 2015:158682.
85. Idowu MO, Kmieciak M, Dumur C., Burton RS, Grimes MM, Powers CN, et al CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43:364-373.
86. Giatromanolaki A, Sivridis E, Fiska A., Koukourakis MI. The CD44 + /CD24-phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol 2011; 28:745-752.
87. Ahmed MA, Aleskandarany MA, Rakha E.A., Moustafa RZ, Benhasouna A, Nolan C, et al A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 2012; 133:979-995.
88. Britton KM, Eyre R, Harvey I.J., Stemke-Hale K, Browell D, Lennard T.W., et al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett 2012; 323:97-105.
89. Kim YS, Jung MJ, Ryu D.W., Lee CH. Clinicopathologic characteristics of breast cancer stem cells identified on the basis of aldehyde dehydrogenase 1 expression. J Breast Cancer 2014; 17:121-128.
90. Liu TJ, Sun BC, Zhao X.L., Zhao XM, Sun T, Gu Q, et al CD133 + cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene 2013; 32:544-553.
91. Zhao P, Lu Y, Jiang X., Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci 2011; 102:1107-1111.
92. Bansal N, Petrie K, Christova R., Chung CY, Leibovitch BA, Howell L, et al Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget 2015; 6:34087-34105.
93. Bartholomeusz C, Xie X, Pitner M.K., Kondo K., Dadbin A, Lee J, et al MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther 2015. [Epub ahead of print].